Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Recommended Global Ophthalmology Webinars & Conferences

Europe & UK
Asia Pacific & Middle East
Canada

Ophthalmology Congress-2023

About Conference


Greetings to my worldwide friends and colleagues.

As we progressively recover from the pandemic of the past two years, I'm happy to let you know that the Ophthalmology Congress 2023 will take place in Frankfurt, Germany, as a fully face-to-face conference. Major worldwide Ophthalmology conferences have already been held in Frankfurt, Germany, and we cordially invite you to visit our lovely nation for the Conference series' long overdue full congress. Since we have been estranged from one another for a very long time, our conference's subject, "Reconnect and Collaborate," seems appropriate.

Frankfurt, Germany fully opened its borders to international travel . Frankfurt is dedicated to welcoming our international delegates in a secure and comfortable setting, with a particular focus on safeguarding their biological safety. In the upcoming months, there should be a rise in the number of international flights to Frankfurt, Germany, and I think that there won't be many restrictions on fully immunized travelers entering Germany.

The planning for the scientific and social schedule of the Ophthalmology Congress 2023 has already started in full swing, and all of the ophthalmologists in Germany are looking forward to your arrival on October 02–03, 2023. Please put these dates in your calendar for what looks to be a highly engaging academic conference with lots of fun social activities and nearby tourism.

 

 

 

 

Session/ Tracks

Track 1:Ophthalmology and Vision Science

The study of ailments relating to the eyes is known as ophthalmology. The doctors that treat this organ surgically and medically are known as ophthalmologists. Ophthalmologists diagnose, treat, and oftentimes even prevent eye conditions and vision impairments. A doctor of ophthalmology may be able to spot symptoms of disorders unrelated to the eyes in addition to providing care for the eyes and eyesight thanks to their medical knowledge. In these situations, they can recommend patients for the right kind of care.

Vision science, an interdisciplinary study of visual systems and perception, includes ophthalmology, optometry, molecular genetics, neurology, and physiological optics. Vision science studies all part of the visual process, including the anatomy, biochemistry, optics, and physiology of the eye. Numerous study topics about how and why eyesight fails in humans, what can be done to prevent it, and how and why it arises in the field of vision science.

  • Optometry
  • Visionary Science
  • Drug Therapy and Pharmacology in Eye Diseases
  • Secondary and Primary Eye Care
  • Tips and Instruments for Ophthalmology Surgery

Track 2:Ophthalmology Chronic conditions and Causes

The majority of people experience visual issues at some point in their lives. While some of the symptoms are minor and will go away on their own, others are easily treated at home. Others need a professional's assistance. Whether your vision has declined or has never improved, there are steps you can do to restore it. A few of the diseases that can affect the eye include infections of the eye or eyelids, genetically inherited eye conditions, eye injuries or objects in the eye, and vision difficulties brought on by conditions affecting several organs (e.g., diabetes or hypertension)

The lack of early signs in many eye problems makes therapy more difficult, and delayed development of visual defects makes the condition harder to treat.

  • Optical Mistakes
  • Macular Degeneration Associated With Age
  • Glaucoma
  • Cataract
  • Diabetes Retinopathy
  • Amblyopia
  • Strabismus
  • Uveitis
  • Lower Vision
  • Recovery from Low Vision
  • Eye pigmentation
  • Eye Thyroid Disorder (TED or Graves Eye Disease)
  • Macular edema due to diabetes
  • Visual impairment

Track 3:Clinical and Experimental Ophthalmology

The anatomy, physiology, histology, and disorders of the eye and its visual system are all covered under the medical discipline of ophthalmology. Our daily lives depend greatly on our ability to see. Clinical ophthalmology is a medical specialty that focuses on the physiology, diseases, and available therapies for the eyes. Clinical ophthalmology treats and diagnoses eye conditions. Many different eye disorders and ailments can be diagnosed using clinical methods. Clinical ophthalmology focuses primarily on the investigation and understanding of a variety of eye disorders as well as the techniques used in ophthalmic patient care. It also covers, among other things, research on ophthalmic surgical techniques, translational research, and ocular medications.

Basic ophthalmology research is done in experimental ophthalmology.

  • Practice of Medicine
  • Ocular Illness
  • Improved Patient Safety and Care Standards
  • Education of the patient and adherence by the patient
  • Compliance/satisfaction with Treatment

Track 4:Optical Health Care

An ophthalmologist is a medical or osteopathic specialist who focuses in treating eye and vision problems. Ophthalmologists are distinct from optometrists and opticians in terms of their training as well as the conditions they may identify and treat. The field of ophthalmology has both opportunities and challenges in the future. Future ophthalmology clinics will be rewarded for offering effective and high-quality care, therefore they must be ready to assist evolving, integrated healthcare systems. High-quality, effective care includes standardized care processes built on established practice norms and matching the level of therapy to the practitioner's level of experience. Ophthalmology has been fortunate over the years to have visionary leaders who have helped us adapt, thrive, and advance the public's eye health.

These qualities should be beneficial to us in the future.

  • Ophthalmology's future trends
  • Problems Ophthalmologists Face
  • Population, economics, computing, and human factors

Track 5:Ocular manifestations of the Coronavirus

The coronavirus's global pandemic has had a significant and enduring impact. There is still much to learn about the condition. Conjunctivitis was once believed to be an ocular symptom of SARS-CoV-2 infection due to several anecdotal and published reports of eye redness and irritation in COVID-19 patients. According to recent study, COVID-19 has been connected to uveitis, Retinovascular, and neuro-ophthalmic disease. It has been determined from the results in the patients' eyes that the SAR-CoV-2 virus can also infect unprotected eyes. The COVID-19 medications also have negative effects on the eyes.

Although long-term use of the antimalarial drugs chloroquine and hydroxychloroquine can harm the retina, this is neither anticipated nor observed with COVID-19.

  • Conjunctivitis Follicular
  • Central Vein Occlusion of the Retina
  • A central retinal artery blocka
  • Mucormycosis
  • Eye inflammation
  • Cranial nerve paralysis
  • Drugs That Can Be Harmful to Your Eyes

Track 6:New Diagnostic Procedures and Techniques

The best solutions to treat their patients more effectively are continually being sought after by ophthalmologists. The creation of diagnostic tools that are more precise and effective is a crucial aspect of this endeavor. The early stages of pars plane vitrectomy, when instrumentation and diagnostic instruments were scarce and the number of entities that could be diagnosed by invasive methods was constrained, saw a tremendous advancement in ophthalmology diagnostic procedures. The use of modern tools has greatly enhanced the treatment of common eye disorders and eye care. As new technologies are developed, the capacity to recognize and address eye issues as well as the general standard of eye care will improve.

  • Non-intrusive Diagnostic Methods
  • Ophthalmology Diagnostic Techniques
  • Diagnostic and therapeutic equipment
  • Diagnostic tests and ophthalmic equipment

Track 7:Ophthalmogenetics

The complex process of developing the normal eye, which takes place in the first trimester of pregnancy, is regulated by a number of genes. A significant eye ailment can arise when these genes make errors (known as mutations). Ophthalmic genetics is a vital and quickly developing topic globally. Global genetic illnesses are on the rise as a result of ethnic diversity and high consanguinity rates. Blindness in persons in their working years is most frequently caused by inherited retinal disease (IRD). The introduction of next-generation sequencing methods and concentrated gene panel analysis, among other molecular genetic advancements, have sped up the process of molecular diagnosis. Likewise, advancements in ocular imaging and measures of visual function have improved our comprehension of natural history.

This is crucial for assessing the effectiveness of treatment in studies using possible IRD medications.

  • Applied Clinical Electrophysiology
  • Therapeutic Trials
  • The use of genes
  • Genomics
  • Phenotypic-genotypic correlation
  • Gene mutagenesis
  • Sequencing of genes
  • Genetic Retinal Disorder
  • Chemical Biology
  • Genetics in Ophthalmology
  • A retinal scan
  • A stem cell

Track 8:Ophthalmology Regeneration

Regenerative ophthalmology (RO) is one of the most active subspecialties of regenerative medicine (RM), which is one of the most exciting areas of the discipline. Congenital degenerations and AMD are just a couple of the conditions that cutting-edge medicines are being tested to cure. By using cells, bioactive compounds, and biomaterials to replace or regenerate tissues and organs, regenerative ophthalmology (RO) aims to restore function. These innovative therapeutic approaches could boost the efficacy and efficiency of the treatment of eye diseases. Researchers from RO have concentrated on the regeneration of lost or damaged eye tissues as a new approach to treating vision impairment and blindness brought on by ocular degenerative conditions, trauma, or infection as a result of the progress of tissue engineering technologies.

  • Ophthalmology using Regenerative Nanotechnology
  • The CRISPR-CA’s System
  • Stem cells, biomaterials, and gene therapy
  • Innovative Regenerative Ophthalmology Tools

Track 9:Eye Tumor’s and Ocular Oncology

Eye tumors, also referred to as ocular tumors, are cancers that affect the eyes. Whether malignant (cancerous) or benign (non-cancerous), a tumor is a mass of cells that are growing abnormally (noncancerous). The most common kind of eye cancers are metastatic tumors. Ocular oncology is the field that studies and treats malignancies that develop in or around the eyes. These tumors can cause vision loss or even the loss of the eye itself, and they can be benign or life-threatening. A specialty in medicine is ocular care for those who have eye cancer. Certainly, the challenges faced differ from those faced in a typical ophthalmology practice.

  • Early cancer detection using biomarkers
  • Supplemental Therapies
  • Following Treatment for Ocular Melanoma, Better Visual Results
  • Nursing Care
  • Ocular Tumor Types
  • The difficulties of ocular oncology

Track 10:Vision Rehabilitation

Rehabilitation, which means "being able again," helps patients restore their independence in terms of their physical, social, emotional, and spiritual well-being. The goal of rehabilitation is not to repair or reverse the causes of the harm, but rather to improve function and independence through adaptation. Vision rehabilitation is a type of medical rehabilitation intended to enhance vision or low vision (also known as vision rehab). In other words, it is the process of improving quality of life and independence for someone who has lost their vision due to illness or injury while restoring functional competence. Optometrists can assist their patients in regaining function, independence, and overall health by providing low vision rehabilitation.

  • Clinical Research and Therapy
  • A neurological perspective
  • Chemical Interventions
  • Physical Method

Track 11:Ophthalmic pathology, optometry, and ophthalmoscopy

The practice of optometry involves examining the eyes and other visual systems for flaws or anomalies, prescription glasses or contact lenses to correct refractive faults, and treating various eye conditions. Optometrists are eye doctors with a focus on routine eye care.

The retina, optic disc, choroid, and blood vessels in the back of the eye are all examined during an ophthalmoscopy technique (fundus). Fundus copy is another name for it. It might be carried out during an eye checkup or as part of a routine physical examination. For assessing the health of the retina, optic disc, and vitreous humor, it is essential.

Ophthalmic pathology is a lab-based science that evaluates samples taken from patients and offers ophthalmologists and other healthcare professionals a diagnosis. For a precise diagnosis, ophthalmic pathologists analyses tissues that have been removed by ophthalmologists. Both a dark and a bright microscope are used to examine the diseased tissue.

  • Exams and Diagnosis of Disease
  • Eye diseases: their causes, etiology, and prognosis
  • contacts and glasses
  • Sky Blue
  • Examining the Fundus Dilatable
  • Grant Photography
  • Grant Research

Track 12:Peripheral vision loss, ocular migraines, and ocular hypertension

Ocular hypertension is a condition when the internal pressure of the eye is elevated above normal. Ocular hypertension can strike anyone at any age, but it strikes African Americans, people over 40, and people with a family history of the condition more frequently. People with diabetes or people who are very nearsighted are also more likely to experience it.

The term "ocular migraine" has been used to characterize a variety of migraine subtypes that are distinguished by aberrant visual symptoms include sight loss, blind spots, zigzag lines, or seeing stars. Unlike other types of migraine, they can happen without any accompanying headache.

The capacity to view items around you without having to move your eyes or turn your head is known as peripheral vision, also referred to as side vision. It also helps with controlling your environment without running into anything and detecting motion around you.

  • Acute Intraocular Pressure
  • Migraine Retinal
  • Ocular Migraine: Understanding & Treatment
  • Ocular Migraine Reactions
  • Factors That Increase Your Risk For Ocular Hypertension, Migraines, and Loss of Peripheral Vision

Track 13:Eye surgery

Ophthalmologists perform surgery on the eye or its adnexa, which is known as eye surgery or ocular surgery. Because the eye is such a delicate organ, particular care must be taken to prevent or minimize future damage before, during, and after surgery. A qualified eye surgeon is in charge of selecting the most appropriate surgical technique for the patient and making sure that all required safety precautions are implemented. The eye has a dense network of nerves, thus anesthesia is necessary. Local anesthetic is the kind of anesthesia that is most frequently used. Eye surgery can be used to treat a variety of conditions, including glaucoma, cataracts, detached retinas, retinal tears, diabetic retinopathy, nearsightedness, and farsightedness.

  • Operation on the retina
  • Eye Plastic Surgery
  • Laser Eye Surgery
  • Trans cataract Surgery
  • Surgery Refractive
  • Surgery for Reconstruction

Track 14:Ophthalmic Care

Primary eye care (PEC) is a broad phrase that refers to using primary healthcare to prevent potentially blinding eye conditions (PHC). PEC includes identifying individuals with preventable causes of blindness as well as the diagnosis and treatment of prevalent eye diseases, particularly those that result in an acute red eye. In every community and region of the world, primary eye care is an essential part in preventing blindness. Without basic eye care, only patients who visit secondary and tertiary clinics will receive a diagnosis and treatment, and little will be done to avoid the condition.

Acute care is required when a patient has a temporary but serious disease, accident, or other eye health issue. Ailments like trachoma, glaucoma, and cataract are treated on a secondary level, in places like hospitals.

  • Eye camps for diagnosis
  • Eye Donation Awareness Programs
  • Easily avoidable causes of blindness

Track 15:Neuro-Ophthalmology

It is simpler to carry out daily tasks if you have good vision. However, vision issues are a common problem. Neuro-ophthalmology is a subspecialty of both neurology and ophthalmology. Eye specialists known as neuro ophthalmologists are experts in neurologically-related vision problems. A physician with particular expertise in the identification and management of neurological and systemic conditions that affect vision and eye movement is known as a neuro-ophthalmologist. Neuro-ophthalmologists have detected a number of illnesses, some of which are not life threatening, while others may worsen and result in irreparable vision loss or even death. The issue might only affect the optic nerve or nervous system, or it might be connected to a more widespread medical condition.

  • Ophthalmologic and Neurologic Sciences
  • Identification and Treatment
  • Neoplastic Diseases that Impact the Oculomotor System

Track 16:Strabismus and pediatric ophthalmology

Pediatric ophthalmology is an intriguing discipline, yet at times it can be upsetting owing to the challenges of evaluating a child. Kid ophthalmologists have more knowledge and expertise diagnosing and treating common pediatric eye problems, even though all ophthalmologists have some training in pediatric eye conditions. Pediatric ophthalmologists are specialists in examining, identifying, and treating eye conditions in newborns, kids, and teenagers. Due to the fact that they perform eye procedures on children, pediatric ophthalmologists are both surgical and medical specialists.

In the case of strabismus, neither eye aligns in the same direction. They aren't staring at the same object at the same moment as a result. The most common kind of strabismus is "crossed eyes." There may be occasional occurrences of the ailment or it may be constant. If it persists throughout a child's formative years, it may result in amblyopia (lazy eyes) and a loss of depth perception.

  • Birth defects of the eyes
  • Problems with eye alignment
  • Children's Eye Conditions
  • Eye disorders diagnosis and treatment

Track 17:Changes of Aging Eyes: Disease and Care

Your eyes change as you get older. Even if some problems become more pervasive as you age, they can affect anyone at any age. Presbyopia is a condition where, as one ages, the lens of the eye becomes less flexible and less able to thicken, which reduces its ability to concentrate on nearby objects. The conjunctiva's mucous cell count may decrease with ageing. As people age, their ability to produce tears may decrease, leaving them less available to keep the eye's surface moist. Both of these alterations contribute to the higher prevalence of dry eyes in elderly persons.

  • Eye disease prevention and treatment
  • Cataract
  • Glaucoma
  • Macular Degeneration Caused by Age
  • Diabetic retinal disease
  • Vision Impairment
  • Age-Related Eye Disorders

Track 18:Laboratory Studies Concerning Ophthalmology

An ophthalmologist is a doctor who focuses on the early detection, evaluation, and treatment of eye conditions. Only when the results will directly affect the patient's care are diagnostic tests frequently ordered. The study and treatment of eye conditions are the focus of the medical specialty known as experimental ophthalmology. It is the laboratory research of vision issues, eye conditions, and the use of medicinal, surgical, and optical interventions. Finding both infectious and noninfectious causes requires diagnostic testing.

  • Lab Equipment
  • Tests for diagnosis

Track 19:Patient Education, patient adherence, and patient satisfaction

Patient education is the process of giving patients and their careers information that will enable them to alter their lifestyle choices or enhance their health. To encourage patient education and engagement, doctors must raise patients' health literacy. Health literacy is the capacity to find, comprehend, and act on health information. In order to produce a therapeutic result, adhesion is described as the patient's "active, voluntary, and collaborative engagement in a mutually acceptable course of activity." The idea of adherence includes both mutuality and choice in the creation of goals, treatment planning, and regimen delivery.

Track 20:Deep learning and artificial intelligence in ophthalmology

Artificial intelligence is the fourth industrial revolution in human history (AI). Recent years have seen a significant increase in interest in deep learning (DL), a family of cutting-edge machine learning techniques. The AI industry has undergone a complete transformation because to the groundbreaking DL AI machine learning technology. In ophthalmology, DL has shown clinically acceptable diagnostic performance in identifying a number of retinal diseases. Future research will be required to evaluate the cost-effectiveness and clinical deployment of various DL systems in clinical practice. The "black-box" component of DL must be explained using both current and emerging methods in order to boost clinical acceptance of DL systems.

  • Fundus Pictures
  • Laser Coherence
  • Imagery and Tomography
  • Eye Imaging
  • "Black-Box" AI algorithms
  • Telemedicine

Track 21:Ophthalmology and Nanotechnology

The frontier of science and technology, nanotechnology is a relatively new idea. It penetrates using nanometer-sized molecules and has proven useful in space exploration, medical research, and other scientific disciplines. The eye is a perfect target for nanotechnology because it is a tiny organ that is accessible due to its exposed placement. According to some sources, "the discovery of nanomedicines has reawakened tremendous aspirations for ocular pharmacotherapy, in which nanostructured pharmaceuticals are projected to pass through the eye's limiting barriers." Adoption of nanotechnology is still hampered by concerns about safe production practices and unanticipated biological effects of nanomaterial use. These obstacles are not insurmountable, and this emerging industry is likely to produce ground-breaking therapies for ocular illnesses.

  • Nanomedicine
  • Nanoscopic pharmaceuticals
  • Nanostructured Medicine

Track 22:New Approaches in Ophthalmology Research

The diagnosis and treatment of diseases and abnormalities of the eyes are the focus of the medical specialty known as ophthalmology. To receive visual information is the function of the human eye. Over the past ten years, there has been a huge advancement in our understanding of ocular illnesses due to the availability and development of novel in vivo imaging technologies. Recent advancements in diagnostic techniques have altered the therapeutic treatments. The field of ophthalmology has recently seen several fascinating developments, notably in anterior segment technologies. In order to diagnose and treat disorders that affect the back of the eye, imaging has become essential. Recent years have seen a rise in the popularity of imaging systems for the anterior segment, which are now often used in clinical settings.

  • Innovations in Diagnosis and Treatment
  • Current Ophthalmology Trends
  • Health Observations
  • A case study

Market Analysis

The Global Ophthalmology Market size was estimated at USD 52.07 billion in 2020, is expected to reach USD 55.28 billion in 2021, and is projected to grow at a CAGR of 6.52% to reach USD 81.05 billion by 2027.

 

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ophthalmology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ophthalmology Market, including Alcon, Alkeus Pharmaceuticals, Bausch + Lomb, Carl Zeiss AG, ClearSight, CooperVision, Envisia Therapeutics, Essex Bio, EssilorLuxottica, Eyenovia, Gensight Biologics, Glaukos Corp, Hoya Corporation, Iris Pharma, Johnson & Johnson Vision, Kubota Pharmaceuticals, LC Technologies, NIDEK CO., LTD., Oraya Therapeutics, PanOptica, PharmOptima, Sensimed, ThromboGenics, Topcon, Topivert, Unimed Pharma, Vision Medicines, VisionCare, and Wellstat Group.

Ophthalmic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The ophthalmic drugs market is expected to register a CAGR of 4.6% during the forecast period (2022 - 2027).

The COVID-19 pandemic disrupted not only the research and development of treatments and medications for illnesses other than COVID-19 but also the global supply chain for drugs and medical products, which had an effect on the market for ophthalmic drugs. For instance, according to an article published by the Public Library of Science in March 2022, titled “COVID-19 pandemic decreased the ophthalmic outpatient numbers and altered the diagnosis distribution in a community hospital in Taiwan: An observational study”, it has been observed that the number of ophthalmic outpatient during the COVID-19 pandemic reduced by 46.9%. In addition, as per the same source, the most significant drop in several ophthalmic outpatients was observed in June with a 60.1% decrease, followed by July (43.3%) and May (38.3%). Also, as per the same source, cataracts (68.2%), refraction and accommodation (55.9%), and macular degeneration (51%) were the top three most frequent diagnoses that had a decline in frequency over the COVID-19 pandemic period. Similarly, according to the research study published by Clinical Ophthalmology, in November 2021, titled “The Impact of Covid-19 in the Follow-Up of Glaucoma Patients in a Tertiary Center: A Comparison Between Pre-Pandemic and Pandemic Periods”, the comparison of the pre-pandemic and pandemic periods data, it was observed that a total number of outpatients clinical visits, visual field exams, surgical procedures and medications released decreased 92.52%, 93.84%, 72.74%, and 19.63%, respectively which shows a significant decrease in the diagnosis and treatment of people with glaucoma during the COVID-19  pandemic.

However, the resumed treatment and diagnosis services and increased hospital visits are expected to increase the demand for ophthalmic drugs, thereby boosting the market growth. The studied market is expected to return to its full potential in time.

Certain factors propelling the market growth include increasing incidences and prevalence of eye-related disorders, rising research and development about the development of novel drugs, and increasing focus on developing combination therapies.

The rising burden of eye-related disorders such as glaucoma, dry eye disease, and other eye-related disorders are the main factor driving the market growth. For instance, according to an article published by Frontiers in Medicine, in December 2021, titled “Estimated Annual Economic Burden of Dry Eye Disease Based on a Multi-Center Analysis in China: A Retrospective Study”, it has been observed that dry eye disease has become the fifth most prevalent ocular condition among women and ninth most prevalent among men in the United States. Additionally, a survey published by the American Journal of Ophthalmology in August 2020, titled “Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey,” reported that DED prevalence ranges from 5% to 15% and increases with age in the United States. Thus, the burden of dry eye diseases is anticipated to drive the studied market growth in the country. Further, according to the October 2021 report of the World Health Organization, about 2.2 billion people around the world have near or distance vision impairment, of which approximately 1 billion cases of vision impairment can be prevented or could have been prevented in 2020. Thus, the high burden of the cases of vision impairment around the world increases the demand for effective treatment and drugs, which is expected to increase the demand for ophthalmic drugs, thereby boosting the market growth.

Moreover, the increasing focus of companies on research and development activities and rising adoption of various business strategies such as mergers and acquisitions, collaborations, and partnerships are further expected to boost growth in the studied market. For instance, in May 2022, Alcon signed an agreement to acquire EYSUVIS (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals, Inc. This acquisition will enhance Alcon’s current offering in the large and currently growing dry eye segment. Additionally, In January 2022, Sun Pharma Canada Inc. launched Cequa (cyclosporine ophthalmic solution 0.09 percent w/v), a calcineurin inhibitor immunomodulator, to treat dry eye disease in Canada. The ophthalmic solution is delivered with nanomicellar (NCELL) technology, which improves cyclosporine’s bioavailability and physicochemical stability to increase ocular tissue penetration.

However, the loss of patent protection for popular drugs in treating eye disorders and the lack of health insurance in developing countries are expected to restrain the growth of the ophthalmic drugs market over the forecast period.

Key Market TrendsThe Anti-glaucoma Drug Segment under Drug Class is Expected to Hold a Significant Share in the Ophthalmic Drugs Market During the Forecast Period

Glaucoma is a group of eye diseases that affect the optic nerve, which is essential for proper vision; excessively high pressure in the eye is often the cause of this group of diseases.

The anti-glaucoma drug segment is expected to witness significant growth in the ophthalmic drugs market over the forecast period owing to the factors such as the increasing prevalence of glaucoma coupled with a rising geriatric population who are more prone to develop glaucoma, which is one of the leading cause of blindness in older adults.

The prevalence of glaucoma is increasing rapidly, which is expected to increase the demand for anti-glaucoma drugs around the world, thus boosting high growth in the segment. For instance, according to the June 2021 report of the BrightFocus Foundation, it has been observed that the most prevalent type of glaucoma, open-angle glaucoma, affects 2.7 million people aged 40 years or above in the United States. Additionally, as per the same source, glaucoma affected over 80 million individuals worldwide in 2020, which is projected to rise to over 111 million by 2040. Thus, with the increasing burden of glaucoma among the population, the demand for anti-glaucoma drugs is expected to increase, further fueling market growth. Also, according to the World Population Ageing Highlight 2020 report published by the United Nations, the global geriatric population is increasing rapidly around the world, and in 2020, about 727 million people of age 65 years or more were living across the world, which was about 9.3% of the total global population. As per the same source, this number is projected to rise to about 1.5 billion people by 2050, accounting for 16% of the global population. Thus, the increasing aging population will significantly impact the studied segment’s growth over the years and is expected to drive the growth in the ophthalmic drugs market.

Similarly, according to the research study published by Cureus, in November 2020, titled “Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future”, it has been observed that Glaucoma is the second leading cause of blindness after cataracts. It develops due to a combination of vascular, genetic, anatomical, and immunological factors and is considered a serious health problem since it can result in irreversible blindness. As per the same study, it was estimated that approximately 57.5 million people around the world were affected by primary open-angle glaucoma (POAG), and 76 million people were suffering from glaucoma in 2020. In addition, this number is projected to reach 111.8 million by 2040. Thus, the increasing number of glaucoma cases in the population is expected to increase the demand for effective anti-glaucoma drugs, which is further expected to increase the market growth over the forecast period.

In addition, with the growing burden of glaucoma, the companies are increasing their focus on developing novel drugs and products for treating patients with glaucoma, which is expected to increase the product launches, thereby propelling the market growth. For instance, in February 2021, Santen Pharmaceutical Korea Co., Ltd. launched glaucoma and ocular hypertension treatment, the EYBELIS Ophthalmic Solution 0.002%, in South Korea after listing in Korea’s national health insurance. Santen Pharmaceutical and Ube Industries, Ltd have filed for the ophthalmic solution’s marketing approval in other Asian countries. Also, in September 2020, Micro Labs USA launched two products, Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL, for the treatment of glaucoma in the United States.

Therefore, due to the above-mentioned factors, the anti-glaucoma drugs segment is expected to hold a significant market share in the studied market.

Asia-Pacific Region is Expected to be Fast Growing Market in the Ophthalmic Drugs Market During the Forecast Period

Asia-Pacific is expected to witness the fastest growth in the ophthalmic drugs market owing to the factors such as the increasing geriatric population, rising prevalence of eye-related disorders, and the presence of key players in the region. For instance, according to the 2021 report of the United Nations Population Fund (UNPF), 4.3 billion people live in the Asia-pacific region, accounting for 60% of the world's population. In addition, as per the same source, the region has the highest prevalence of eye disorders which is a major driver in the expansion of the ophthalmic drugs market in the Asia-Pacific region. Additionally, according to a research study published by Frontiers in Medicine in July 2021, titled "Prevalence of primary open-angle glaucoma in the last 20 years: a meta-analysis and systematic review", the global population with primary open-angle glaucoma (POAG) was estimated to be over 68.56 million in 2020, with Asia accounting for approximately 53% of them. In addition, this number is projected to rise to about 78.34 million by 2030. Thus, the increasing burden of eye-related disorders is expected to increase the demand for ophthalmic drugs, thereby boosting the market growth.

Further, the rising geriatric population in the region and other risk factors such as hypertension and diabetes are expected to increase the burden of eye disorders, which is expected to positively impact the growth of the studied market in the Asia-Pacific region. For instance, according to a 2021 report from the United Nations Population Fund (UNPF), the number of elderly people in Asia-Pacific is expected to more than quadruple by 2050, rising from 630 million in 2020 to over 1.3 billion.

Moreover, the increasing product and drug launches and the rising focus of the companies in research and development activities are further expected to boost the studied market in the region. For instance, in September 2021, the Center for Drug Evaluation, China National Medical Products Administration, approved Arctic Vision's Investigational New Drug (IND) application for a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia (CDE, NMPA).

Therefore, due to the above-mentioned factors, the Asia-Pacific region is expected to occupy a significant share in the studied market over the forecast period of the study.

Competitive Landscape

The market studied comprises a combination of both small and large firms and is fairly competitive. Most big companies focus on research and development to bring innovative products to the market. Some of the major players in the ophthalmic drugs market are Aerie Pharmaceuticals Inc., AbbVie (Allergan), Bausch Health, Bayer AG, F. Hoffmann-La Roche Ltd, Hoya Corporation, Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals Inc.

Join us in Frankfurt, Germany on October 02-03, 2023, for the “33rd World Congress on Ophthalmology and Optometry” 

Ophthalmology Congress 2023 focuses on the most recent innovative improvements and research in the field of Ophthalmology, which focuses on the most recent, creative developments and ophthalmology-related research.

We bring together a distinctive and global mix of major and minor pharmaceutical, biotech, and diagnostic firms, top academic institutions for clinical research, orthoptists, deans, researchers, and scholars.

Ophthalmology: The area of medicine that studies the anatomy, physiology, disease, and other features of the eye.

An expert in eye care is an ophthalmologist. Ophthalmologists, in contrast to optometrists and opticians, are medical doctors (MDs) or osteopathic doctors (DO) who have specialized training and expertise in the diagnosis and treatment of eye and vision diseases. Ophthalmologists are trained to provide both medical and surgical care for the eyes.

Past conference report

Ophthalmology Congress 2022

ConferenceSeries hosted the event “32nd World Congress on Ophthalmology and Optometry” which was held on November 21-22, 2022 Rome, Italy. The conferences were organized with a focus on the themes “Exploring New Technique and innovation in ophthalmology” was a great success where eminent keynote speakers from various reputed companies and Universities made their resplendent presence and addressed the gathering.

The event proceedings were carried out through several Scientific-sessions and plenary lectures, ConferenceSeries would like to express a sincere thankfulness to all the Honourable guests and Keynote Speakers of Ophthalmology and Optometry. We would like to convey a warm gratitude to all the Honourable guests and Keynote Speakers of OPHTHALMOLOGY CONGRESS 2022.

OPHTHALMOLOGY CONGRESS 2022 committee would like to convey a warm gratitude to all the Honorable guests and Keynote OPHTHALMOLOGY CONGRESS 2022 committee would like to convey a warm gratitude to all the Honorable guests and Keynote Speakers Mikhail A. Ostrovsky, Fabrizio Bonucci, Enric Bach Cuadra, Naj Sharif, Shlomo Dotan, Roshini Sanders, Ioanna Triantafyllopoulou have given a wonderful talk which makes allows the delegates and other attendees to gain the knowledge about main course of the event.

Ophthalmology congress2022 organizing Committee would like to thank the Moderator of the conference, Enric Bach Cuadra from Polytechnic University of Catalonia Spain, who contributed a lot for the smooth functioning of this event and for taking up the responsibility to coordinate during the sessions for smooth functioning of this event. We are indebted to your support.

We also would like to thank all our Speakers, Poster Presenters and Delegates for taking out your time and sharing their research work with our peer network. We are very glad to have shared a great relationship with all these Attendees, associations and we hope to see even greater support in our upcoming events. We would also like to thank Chairs and Co-chairs of the conference Speakers Mikhail A. Ostrovsky, Fabrizio Bonucci, Enric Bach Cuadra, Naj Sharif, Shlomo Dotan, Roshini Sanders, Ioanna Triantafyllopoulou for a being a great support for our event to be a grand success.

A series of lectures by distinguished professionals discussed the recent trends and issues in inter-disciplinary Rheumatology and its technical advancements.

Save your dates for the most awaited event of  2023

With a great response and feedback which we received from participants and supporters from Rheumatology 2022, we are proud to announce our upcoming conferences in the Series 33rd World Congress on Ophthalmology and Optometry October 02-03, 2023 Frankfurt, Germany with the theme of “Exploring New Technique and innovation in ophthalmology”

The main aim of this conference is to solicit the gracious presence of our honourable, to the upcoming conference“33rd World Congress on Ophthalmology and Optometry October 02-03, 2023 Frankfurt, Germany” that is going to be held during October 02-03, 2023 Frankfurt, Germany, to share and exchange their knowledge. 

It is an International platform for business delegates, B2B meetings, poster presentations, workshops, symposia, networking and more. It will offer a platform wherein you can ensure enormous exposure and networking by exhibiting products and services. Grab the opportunities, and share your innovative ideas, new technologies and Recent researches.

Ophthalmology Congress 2022 witnesses an amalgamation of peerless speakers who enlightened the gathering with their contribution towards the prevention of Rheumatology related difficulties, its effects and treatment on Rheumatology.

For being a Experts in Rheumatology and Ophthalmology, we hope that this platform gives knowledge and new updates by undergoing with the several interactive sessions to encourage the exchange of innovative ideas in the field of Rheumatology and its advancements, in that all the session talks are consider to be a great talks which makes the delegates, exhibitor, collaborators and other speakers feels so much interesting.

Being a significant expert in this area we would like to Invite you as an International Organizing Committee Members, Speakers, Keynote speakers, Young Research forum, Sponsors and Exhibitor, etc for Ophthalmology 2022. Our goal is to deliver an outstanding program which covers the entire spectrum of research & innovations in Otology, Rhinology, Laryngology and share the cross-cultural experiences of various principles and practices.

The centre of the activity of Rheumatology 2020 is to produce the clear visual definition by undergoing with Oral Presentation, Poster presentation, Workshop, Exhibition, networking and interacting session

With the feedback from your renowned Speakers, we have added some of the new Session tracks that needs to be focused such as such as Clinical Ophthalmology Retina and Retinal Detachment, Optometry & Vision Science,Glaucoma,.Latest Research in Ophthalmology and Vision Improvement,Cornea Disorders and Treatments,Macular Degeneration,Ocular Oncology,Paediatric & Strabismus,Neuro Ophthalmology,Lens and Cataracts,Diabetic Retinopathy,Medicine in Ophthalmology,Astigmatism,Vision Rehabilitation,OphthalmologyDisorders,Eye Transplant,Oculoplastics and Orbit Surgery,Ophthalmic Drug Delivery,Orbital Disorders,Ophthalmology Practice,Cataract and Refractive Surgery,Keratoprosthesis,Veterinary Vision,Latest and Innovative Eye Research.

With the great support we have successfully completed Rheumatology 2019 and we are expecting huge response and support from the Rheumatology and Arthroplasty Doctors, Rheumatology and Arthroplasty Professionals, Young researchers, Students, Delegates, Directors and other Rheumatology and Arthroplasty related companies to have your gracious presence at 32nd World Congress on Ophthalmology and Optometry” which was held on November 21-22, 2022 Rome, Italy to make this congress a great successful event of the year 2022

Join our team Ophthalmology 2023 at this beautiful city of Frankfurt, Germany and let’s make this professional gathering a Great success.

 

To Collaborate Scientific Professionals around the World

Conference Date October 02-03, 2023

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Supported By

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by